Literature DB >> 32594336

Bupropion Ameliorates Acetic Acid-Induced Colitis in Rat: the Involvement of the TLR4/NF-kB Signaling Pathway.

Amir Rashidian1,2, Pegah Dejban1,2, Kiana Karami Fard3, Alireza Abdollahi4, Mohsen Chamanara5, Ahmadreza Dehpour1,2, Amin Hasanvand6.   

Abstract

Inflammatory bowel disease composed of ulcerative colitis and Crohn's disease is a disorder that may involve entire gastrointestinal tract. Its pathogenesis is mainly an immune-mediated inflammation. Recently, it has been indicated that bupropion possesses anti-inflammatory properties; hence, the objective of this experiment is the investigation of the anti-inflammatory influence of bupropion on colonic lesions that emerged following the intrarectal administration of acetic acid. Thirty-six male Wistar rats were allocated randomly into six groups, including control, acetic acid, dexamethasone (2 mg/kg), and bupropion (40, 80, and 160 mg/kg). Colitis was induced by intrarectal administration of acetic acid in all study groups except control group, and animals were treated by oral administration of dexamethasone and bupropion. While macroscopic and microscopic lesions were observed after colitis induction, administration of dexamethasone and bupropion 160 mg/kg led to the remarkable improvement in lesions. In addition, the expression of TLR4 and NF-ĸB was decreased after colitis induction; however, treatment with dexamethasone (2 mg/kg) and bupropion (160 mg/kg) resulted in a significant decrease in their expression. Regarding biochemical factors, following colitis induction, TNF-α level and MPO activity were increased; nevertheless, dexamethasone (2 mg/kg) and bupropion (160 mg/kg) decreased the TNF-α and MPO activity. In conclusion, bupropion exerts anti-inflammatory influence through suppressing the TLR4 and NF-ĸB expression in the rat model of acute colitis.

Entities:  

Keywords:  TLR4/NF-kB signaling pathway; acetic acid; bupropion; inflammatory bowel disease

Year:  2020        PMID: 32594336     DOI: 10.1007/s10753-020-01273-2

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  37 in total

Review 1.  Role of Toll-like receptors in inflammatory response in macrophages.

Authors:  A Aderem
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

2.  Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis.

Authors:  Seth Rakoff-Nahoum; Justin Paglino; Fatima Eslami-Varzaneh; Stephen Edberg; Ruslan Medzhitov
Journal:  Cell       Date:  2004-07-23       Impact factor: 41.582

Review 3.  Emerging immunological targets in inflammatory bowel disease.

Authors:  Giovanni Monteleone; Francesco Pallone; Thomas T MacDonald
Journal:  Curr Opin Pharmacol       Date:  2011-10-12       Impact factor: 5.547

Review 4.  Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.

Authors:  Stephen B Hanauer
Journal:  Inflamm Bowel Dis       Date:  2006-01       Impact factor: 5.325

5.  Regulation of Toll-like receptor 4 expression in mouse colon by macrophage migration inhibitory factor.

Authors:  Tatsuya Ohkawara; Hiroshi Takeda; Kencho Miyashita; Morie Nishiwaki; Toshinori Nakayama; Masaru Taniguchi; Takashi Yoshiki; Junji Tanaka; Junji Takana; Masahiro Imamura; Toshiro Sugiyama; Masahiro Asaka; Jun Nishihira
Journal:  Histochem Cell Biol       Date:  2005-12-07       Impact factor: 4.304

6.  Qing Hua Chang Yin exerts therapeutic effects against ulcerative colitis through the inhibition of the TLR4/NF-κB pathway.

Authors:  Xiao Ke; Fan Zhou; Youliang Gao; Bingying Xie; Guanghong Hu; Wenyi Fang; Jun Peng; Youqin Chen; Thomas J Sferra
Journal:  Int J Mol Med       Date:  2013-07-29       Impact factor: 4.101

Review 7.  IL-10 and its related cytokines for treatment of inflammatory bowel disease.

Authors:  Ming-Cai Li; Shao-Heng He
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

8.  Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial.

Authors:  Mark J Eisenberg; Sonia M Grandi; André Gervais; Jennifer O'Loughlin; Gilles Paradis; Stéphane Rinfret; Nizal Sarrafzadegan; Sat Sharma; Claude Lauzon; Rakesh Yadav; Louise Pilote
Journal:  J Am Coll Cardiol       Date:  2013-02-05       Impact factor: 24.094

9.  Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification.

Authors:  Arie Levine; Anne Griffiths; James Markowitz; David C Wilson; Dan Turner; Richard K Russell; John Fell; Frank M Ruemmele; Thomas Walters; Mary Sherlock; Marla Dubinsky; Jeffrey S Hyams
Journal:  Inflamm Bowel Dis       Date:  2010-11-08       Impact factor: 5.325

10.  Heme activates TLR4-mediated inflammatory injury via MyD88/TRIF signaling pathway in intracerebral hemorrhage.

Authors:  Sen Lin; Qing Yin; Qi Zhong; Feng-Lin Lv; Yu Zhou; Jing-Qi Li; Jing-Zhou Wang; Bing-yin Su; Qing-Wu Yang
Journal:  J Neuroinflammation       Date:  2012-03-06       Impact factor: 8.322

View more
  1 in total

1.  Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3.

Authors:  Alireza Karimollah; Anahid Hemmatpur; Taha Vahid
Journal:  Inflammopharmacology       Date:  2021-07-03       Impact factor: 4.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.